BofA lowered the firm’s price target on Pfizer (PFE) to $26 from $27 and keeps a Neutral rating on the shares. The firm adjusted several targets in conjunction with its Q1 preview for its large-cap pharma and small-to-mid cap biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Option traders moderately bearish in Pfizer with shares down 2.5%
- Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
- Pfizer Targets Advanced Kidney Cancer With New PF-08634404 Trial: What Investors Should Know
- Mixed options sentiment in Pfizer with shares down 1.57%
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports